Cancer-killing CAR therapies gain speed

In recent clinical trials, engineered CAR T cells have yielded response rates as high as 90% in patients with leukemia. Now, scientists are working to get this therapy to market and possibly expand its use into solid tumors.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer discovery 2015-01, Vol.5 (1), p.7-7
1. Verfasser:	Weber, Melissa
Format:	Artikel
Sprache:	eng
Schlagworte:	Humans Immunotherapy Neoplasms - immunology Neoplasms - therapy Receptors, Antigen, T-Cell - genetics Receptors, Antigen, T-Cell - metabolism Recombinant Fusion Proteins - genetics Recombinant Fusion Proteins - metabolism T-Lymphocytes - immunology T-Lymphocytes - metabolism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	In recent clinical trials, engineered CAR T cells have yielded response rates as high as 90% in patients with leukemia. Now, scientists are working to get this therapy to market and possibly expand its use into solid tumors.
ISSN:	2159-8274 2159-8290
DOI:	10.1158/2159-8290.CD-ND2014-013